Get started

Therapeutics

Avidity Biosciences (RNA) Analysis RNA Therapeutics Leadership: Avidity Biosciences NASDAQ:RNA is at the forefront of RNA therapeutics with its innovative antibody-oligonucleotide conjugates (AOCs). Its lead candidate, Del-desiran (AOC 1001), targeting myotonic dystrophy type 1, is on the verge of a pivotal trial. Approval could significantly boost earnings. Strategic Partnership: Avidity's partnership with Bristol Myers Squibb, valued at up to $2.3 billion, focuses on cardiovascular targets, expanding their collaboration and enhancing the potential for groundbreaking treatments. Clinical Milestones: A major clinical update for AOC 1001 is expected by mid-2025. Success in this trial could validate Avidity’s platform and unlock significant value. Additionally, the company is developing treatments for Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Investment Outlook: Bullish Outlook: We are bullish on RNA above the $24.00-$24.50 range. Upside Potential: With a target set at $34.00-$35.00, Avidity's innovative approach and diversified pipeline present significant growth potential. 📊🧬 Stay informed about Avidity Biosciences for promising investment opportunities! #RNA #Therapeutics 📈🔍
NASDAQ:RNALong
by Richtv_official
Janux Therapeutics Makes Strides in Prostate Cancer TreatmentJanux Therapeutics ( NASDAQ:JANX ) has made waves with promising interim early-stage data for its experimental therapy targeting advanced prostate cancer. Shares of the drug developer skyrocketed, more than doubling in value following the announcement, as investors rallied behind the optimistic trial results. Groundbreaking Trial Data The candidate, JANX007, demonstrated remarkable efficacy in reducing prostate-specific antigen (PSA) levels in a majority of the 23 patients who received the drug. Furthermore, deeper reductions were observed at higher doses, signaling the potential for significant clinical impact. PSA, a critical biomarker used in diagnosing and monitoring prostate cancer, underscores the significance of these findings in advancing treatment options for patients facing this challenging disease. TD Cowen analyst Marc Frahm hailed the data, emphasizing JANX007's multi-billion-dollar potential in revolutionizing prostate cancer therapy. The positive outcomes reflect Janux Therapeutics' commitment to innovation and its dedication to addressing unmet medical needs in oncology. Expanding Therapeutic Portfolio In addition to JANX007, Janux Therapeutics ( NASDAQ:JANX ) reported encouraging interim early-stage data for JANX008, targeting advanced or metastatic solid tumors characterized by high levels of a protein associated with cancer cell proliferation. This expansion of the therapeutic pipeline underscores the company's comprehensive approach to combating cancer across multiple fronts. Addressing Treatment Challenges Janux's focus on tumor-activated immunotherapies represents a promising strategy in overcoming challenges such as cytokine release syndrome (CRS), a significant toxicity issue encountered in cancer treatment. By developing therapies that harness the body's immune system to selectively target tumor cells, Janux aims to minimize adverse effects and enhance treatment efficacy. Market Impact and Future Prospects The surge in Janux Therapeutics' ( NASDAQ:JANX ) stock value reflects investor confidence in the company's innovative approach and the potential of its therapeutic candidates. With a market debut on the Nasdaq in 2021, Janux continues to garner attention as a key player in the evolving landscape of cancer therapeutics. As Janux Therapeutics ( NASDAQ:JANX ) advances its clinical programs and explores new avenues for therapeutic development, the company remains poised to make significant contributions to the fight against cancer. The positive trial results for JANX007 and JANX008 underscore the promise of precision medicine in transforming cancer care and improving patient outcomes. In summary, Janux Therapeutics' ( NASDAQ:JANX ) recent achievements mark a milestone in the quest for more effective and targeted treatments for prostate cancer and other solid tumors. With continued momentum and a commitment to innovation, Janux stands at the forefront of advancing the frontiers of cancer therapy.
NASDAQ:JANXLong
by DEXWireNews
Voyager Therapeutics' ($VYGR) Breakthrough In a groundbreaking move within the biotechnology sector, Voyager Therapeutics recently announced a strategic licensing deal with Novartis, catapulting its shares up by an impressive 35% in premarket trading. The collaboration involves Novartis making an upfront payment of $100 million to gain exclusive access to Voyager's cutting-edge RNA-based screening platform and to advance a promising gene therapy candidate targeting Huntington's disease (HD). This alliance not only signifies a significant financial boost for Voyager but also opens up a pathway to revolutionize the treatment landscape for Huntington's disease. Key Deal Highlights: The $100 million upfront payment from Novartis is a testament to the immense potential perceived in Voyager's technology and the promising gene therapy candidate currently in the pre-clinical stage for Huntington's disease. As part of the agreement, Voyager stands to receive substantial milestone payments, amounting to up to $1.2 billion, reflecting Novartis' confidence in the successful development and commercialization of the therapy. Furthermore, Voyager is entitled to tiered royalties on global net sales of products utilizing its RNA-based screening platform, providing a long-term revenue stream. Technical Analysis Signals Positive Momentum: From a technical analysis perspective, Voyager Therapeutics has broken through the ceiling of a falling trend channel in the medium to long term. This breakout suggests a potential shift in the stock's trajectory, signaling either a slower descent initially or the initiation of a more horizontal development. The stock currently finds support at $8.00 and faces resistance at $10.80. Positive volume balance indicates a strong presence of aggressive buyers, while sellers appear to be more passive, further strengthening the stock's position. Why Buy Voyager Therapeutics Stock Now: 1. Strategic Partnership: The collaboration with Novartis positions Voyager as a key player in the gene therapy space, validating the potential of its RNA-based screening platform. 2. Financial Boost: The $100 million upfront payment and the possibility of up to $1.2 billion in milestone payments underscore the financial viability and growth potential of Voyager Therapeutics. 3. Huntington's Disease Focus: With a gene therapy candidate specifically targeting Huntington's disease, Voyager is addressing an unmet medical need and contributing to advancements in treating genetic disorders. 4.Technical Breakout: The technical analysis signals a positive momentum shift, suggesting a potential upward trend. The stock's support at $8.00 and resistance at $10.80 provides a clear framework for potential gains. Voyager Therapeutics' recent licensing deal with Novartis has injected new life into the biotech firm, sparking optimism among investors. The financial infusion, strategic partnership, and positive technical signals make Voyager an attractive prospect for buyers seeking exposure to the rapidly evolving field of gene therapy. As the company advances its pre-clinical gene therapy candidate for Huntington's disease, investors stand to benefit from the potential growth and transformative impact of this collaboration on the future of genetic disorder treatments.
NASDAQ:VYGRLong
by DEXWireNews
SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some even bought the $210 strike price! They also have a big partnership with the giant Roche Holding AG (RHHBY). I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon! Looking forward to read your opinion about it.
NASDAQ:SRPTLong
by TopgOptions
ACRS Aclaris Therapeutics Potential BuyoutACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025. ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023. ACRS reached 52 week low today: $5.05. Analysts Price Targets: $21 The Goldman Sachs Group $29 BTIG Research $38 Cantor Fitzgerald $43 HC Wainwright Considering the above, I think ACRS might be an easy +3X! Looking forward to read your opinion about it.
NASDAQ:ACRSLong
by TopgOptions
3
FATE | Incoming Rally - Oversold | LONGFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
NASDAQ:FATELong
by DivergenceSeeker
1
$PSIL Bombed out #Weed #ETF $MSOS attacking resistance lines...Will it pull up the AdvisorShares Psychedelics ETF? Strength in the #Biotech sector would also be a friendly situation. here are the top holdings: CMPS COMPASS PATHWAYS PLC 13.12% ATAI ATAI LIFE SCIENCES NV 9.73% CYBN CYBIN INC 7.97% SEEL SEELOS THERAPEUTICS INC 6.90% ITCI INTRA-CELLULAR THERAPIES INC 6.44% HUGE FSD PHARMA INC-CLASS B 5.82% SAGE SAGE THERAPEUTICS INC 5.23% ALKS ALKERMES PLC 4.84% DRUG BRIGHT MINDS BIOSCIENCES INC 4.70% I can see this ETF targeting $3.2 as its first port of call.
AMEX:MSOSLong
by BallaJi
Pox Vaccine/Treatment Long, Dark WinterWith the small rise of pox news going on in the U.S., be it the second case of monkeypox this year , to smallpox vials found at a vaccine research facility in Pennsylvania, it brings to question as to whether or not health companies that have the capability to manufacture vaccines, treatments, and test kits against smallpox will be the new growth sector of vaccine stocks in the future. Although smallpox is considered eradicated since 1980, considering other variants of smallpox like monkeypox are still present in this world and the lack of immunity among the young (people under the age of 35) from the closure of smallpox vaccine production (we're talking about a ~ 15% fatality rate that goes up to ~40% the younger a person is ), it is still a clear and present danger to society. Doesn't help that the FDA has been more active in approving multiple vaccines and treatments over the last 3 years. . Though the good news is that the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) will target to stockpile enough vaccines for every American according to a 2016 report . PREVENTION As of my knowledge, the following stocks hold a trademark of a vaccine against smallpox: - $EBS, ACAM2000 ® - $BVNRY, holds a trademark of a vaccine against monkeypox, named JYNNEOS® under the FDA . For tradenames of this vaccine under other regions, see the investor news page published this july .Note the JYNNEOS vaccine is the only currently FDA-approved vaccine for the prevention of monkeypox disease and smallpox. These vaccines are not readily available to public, but several treatments are ... more on that below. - $SNY, the Aventis Pasteur Smallpox Vaccine (APSV), that is available in the event that ACAM2000® is depleted within the U.S. Strategic National Stockpile (SNS) which apparently holds 90M doses . Note Aventis was merged with Sanofi in 2004, just to clear up any confusion on any old web pages from before 2004. More details about these vaccines can be found here: www.cdc.gov www.cdc.gov www.fda.gov You could argue $NVAX to be a good pick but I would consider it a long-term play. TREATMENTS The following stocks hold a trademarked treatment against smallpox: - $SIGA , TPOXX® , also known as tecovirimat and ST-246® - $CMRX , Tembexa (brincidofovir) There are many more companies working on treatments/detections against smallpox, so feel free to research and find them before they go public. This idea is merely an inspiration for you to look for and capitalize on this opportunity if it presents itself in the future. Take BioFire as an example, a private company contracted by the DoD to supply them test kits on various biological warfare agents including smallpox . ( Pg 105 of 2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan). But although there private, they've merged w/ bioMerieux , a publicly-traded company, in January 2014. In the event that the supply of vaccines does meet demand, this could be an alternative strategy seeing as test detection kits may not be in demand at the moment. Especially considering that the awarded NGDS contract was valued at $240M for a period of 8 years, or $30M per year(which corresponds very closely with how much $ was allocated toward JOINT BIOLOGICAL AGENT DECONTAMINATION SYSTEM (JBADS) according to the UNCLASSIFIED Department of Defense Fiscal Year (FY) 2022 Budget Estimates document released in May this year on Page 2 of 91, P-1 line #80 titled CB Protection & Hazard Mitigation, or just page 142 of 754 of the pdf doc). With each kit costing $8K-$9k each for 30 tests , at max the DoD should hold ~30K kits assuming these kits have not been used and have an extended shelf life beyond the lifetime of the awarded gov. contract, and that this budget does not include any other products from BioFire related to the NGDS. 30K units with 30 tests each means 900,000 total possible tests... if they're single-use, it may not be even enough for essential personnel contracted by the gov. Even if you consider smallpox's eradication... it is not reasonable for the gov to spend a bit more on these kits seeing they cover detection on outbreaks outside of smallpox like anthrax, ebola, etc. Thankfully Bill Gates did warn us of bioterror attacks concerning smallpox earlier this year. The same goes for U.S. Government agencies and institutions' wargaming of such an event back in 2001, naming the exercise, Dark Winter . A couple of interesting conclusions from this exercise: -No surge capacity in U.S. healthcare and public health systems. Given how COVID-19 went, not too surprising but as expected -Information management w/ media be crucial for crisis control. Lol, w/ the amount of distrust in the media and gov. this will be sh*tshow. Don't be surprised by draconian levels of control over the flow of info if this outbreak happens. -Renewed vaccine production is estimated to require at least 24-36 months. Big yikes. If a smallpox breakout does happen and vaccine hesitancy continues w/ smallpox vaccines, let alone the supply of these products not being able to catch up to their demand, expect a high amount of casualties and stocks related to the treatment rather than the prevention of smallpox to rise. Nonetheless, the living will be capable of seeing a new and brighter world of the 4th industrial revolution by 2030. Feel free to comment below on any constructive criticism against this idea. I'd like to strengthen it and improve on the quality of future ideas. If my grammar is bad, it is no excuse, but I was raised with poor primary education, it will get better with time. If you agree with this idea, feel free to leave a like and share, thank you.
NASDAQ:SIGALong
by linebands
CWBR CohBar retracement completed ! Buy opportunity? CWBR CohBar is developing mitochondria based therapeutics for the treatment of age-related diseases. So it`s an anti-aging listed companies. They released positive topline results from an early stage study into CB4211, a drug under development for the treatment of nonalcoholic steatohepatitis, but after a 70% increase, the stock went even lower than before the pump. WBB Securities upgraded CohBar, Inc. stock to Buy from Speculative Buy with a price target of $5. On 4/23/2021 Maxim Group brokerage Initiated Coverage with a Buy rating and a price target of $3.00 The Market Cap is only 72.138M I see a lot of potential in this stock! Do you?
CLong
by TopgOptions
MRKR (Marker Therapeutics, Inc): Something with huge Risk:RewardHello folks MRKR (Marker Therapeutics, Inc) still sleeping but its worth to thinking about. Why? MARKER THERAPEUTICS is a clinical-stage immuno-oncology c NASDAQ:MRKR ompany, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Company news are incredibly good and forecast of stock is very bright because they find to But this symbol needs some confident from traders. Today's price is interesting for value investors. MRKR is one of the under-radar stocks. we love it! Now what? We added more to this symbol and details are below: Target 1: 5.95 USD (%160 Reward) Target 2: 7.90 USD (%250 Reward) Stop Loss: 2.00 USD (%10 Risk) Entry Type: Buy Limit Entry Point: 2.25 Risk Reward Ratio: 1:16 & 1:24 Stay safe and refer us to your friends and follow us for new ideas. More data for who like to read: "We are pleased with the results of the safety lead-in portion of the trial, in which all six patients met the safety endpoints following infusion of our MultiTAA-specific T cell therapy," said Mythili Koneru, M.D., Ph.D., Chief Medical Officer of Marker Therapeutics. "We are currently enrolling patients in the main portion of our first Company-sponsored trial and continue to activate clinical sites across the U.S. We are looking forward to further advancing MT-401 in this disease setting. Despite recent advances in how hematological malignancies are treated, patients remain in urgent need of new therapeutic options." About Marker's Phase 2 AML Post-Transplant Study The multicenter Phase 2 AML study is evaluating the clinical efficacy of MT-401 in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting. In the adjuvant setting, approximately 120 patients will be randomized 1:1 to either MT-401 at 90 days post-transplant versus standard-of-care observation, while approximately 40 patients with active disease will receive MT-401 as part of the single-arm group. The primary objectives of the trial are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients. Additional objectives include, for the adjuvant group, overall survival and graft-versus-host disease relapse-free survival while additional objectives for the active disease group include overall response rate, duration of response, progression-free survival and overall survival. In April 2020, the FDA granted Orphan Drug designation to MT-401 for the treatment of patients with AML following allogeneic stem cell transplant. Forward-Looking Statements This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401; and the overall market opportunity for our product candidates. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at sec gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
NASDAQ:MRKRLong
by StockAndMoreCom
20-150% Profits Possible on SEEL Therapeutics My favorite new indie stock, Seelos Therapeutics, was recently upgraded from a price target of $4.70 to a whopping $15. For this to happen, it may have to beat some bears (in SPY) and sharks (in short interest). Short interest in the stock is down, with most shares not available to short. This is positive and bullish for shorter term. The stock market looks to continue its rally, with minor downs, as usual, until further notice. Biden's Infrastructure Plan may continue to stimulate the market to amazing new highs. I may invest in this on Monday. I really need to make some $$ for food, rent, and my beloved kitten. If it follows DLPN (Dolphin Entertainment), it may even beat its updated price target! DLPN was a rocket ship this year! Everyone go out and see some seals! News had it that the Great White Sharks of Cape Town have disappeared this year! Enough synchronicities, this is an ethical company that works on healing chronic diseases. Resources: stockinvest.us stocktwits.com finance.yahoo.com www.nasdaq.com seekingalpha.com investorshub.advfn.com seelostherapeutics.com #mayweallgetrichtogether
SLong
by Grandmaster76
Onconova Therapeutics (NASDAQ: $ONTX) Looking Juicy This MorningOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in the first half of 2021, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab. Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.
OLong
by Bullishcharts
21